Implantica Publishes Interim Report for January - June 2026

Implantica has published its interim report for the first half of 2026, covering the period from January to June. The report details the company's financial performance and key events during the second quarter.

During the reporting period, sales of Implantica's RefluxStop® product increased by more than 60% when compared to the same period in the previous year. This growth reflects the product's ongoing market penetration and customer reception.

The company is undertaking strategic preparations for the future and has received FDA approval for RefluxStop®. This clearance marks a significant step for the company's growth and expansion into the United States market.

Implantica anticipates that these developments will support future success and solidify its position within the medical device sector.